{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:43:02Z","timestamp":1776080582104,"version":"3.50.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L232017"],"award-info":[{"award-number":["L232017"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471380"],"award-info":[{"award-number":["82471380"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.msard.2025.106351","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T16:32:51Z","timestamp":1740241971000},"page":"106351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Advances in maintenance therapies for neuromyelitis optica spectrum disorders: A new era of targeted drugs"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-1525","authenticated-orcid":false,"given":"Yingjie","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3618-8271","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106351_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073829","article-title":"Mesenchymal stem cell-derived extracellular vesicles and their therapeutic use in central nervous system demyelinating disorders","volume":"23","author":"Allegretta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106351_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1166490","article-title":"Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: a systematic review and network meta-analysis","volume":"14","author":"Aungsumart","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ene.14105","article-title":"Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis","volume":"27","author":"Baker","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0004","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106351_bib0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2017.04.001","article-title":"Expansion of IL-6(+) Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients","volume":"307","author":"Barros","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106351_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102538","article-title":"Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects","volume":"46","author":"Brod","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106351_bib0007","doi-asserted-by":"crossref","first-page":"e1732","DOI":"10.1212\/WNL.0000000000008394","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica","volume":"93","author":"Burt","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106351_bib0008","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41589-022-01115-2","article-title":"The landscape of targets and lead molecules for remyelination","volume":"18","author":"Caprariello","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.msard.2025.106351_bib0009","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106351_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155304","article-title":"Hematopoietic stem cell transplantation in neuromyelitis optica-spectrum disorders (NMO-SD): state-of-the-art and future perspectives","volume":"21","author":"Ceglie","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106351_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5120107","article-title":"Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: insights from preclinical studies","volume":"5","author":"Chen","year":"2016","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2025.106351_bib0012","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3389\/fphar.2019.01373","article-title":"C16 peptide promotes vascular growth and reduces inflammation in a neuromyelitis optica model","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.msard.2025.106351_bib0013","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0014","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.msard.2025.106351_bib0015","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106351_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.650708","article-title":"Baricitinib ameliorates experimental autoimmune encephalomyelitis by modulating the Janus Kinase\/signal transducer and activator of transcription signaling pathway","volume":"12","author":"Dang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106351_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22157925","article-title":"Cells to the rescue: emerging cell-based treatment approaches for NMOSD and MOGAD","volume":"22","author":"Derdelinckx","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106351_bib0018","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2019.06.018","article-title":"TLR-2 and TLR-4 agonists favor expansion of CD4(+) T cell subsets implicated in the severity of neuromyelitis optica spectrum disorders","volume":"34","author":"Dias","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106351_bib0019","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/cns.13904","article-title":"Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: a single-center, single-arm, open-label study","volume":"28","author":"Ding","year":"2022","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.msard.2025.106351_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118217","article-title":"Effect of NMO-IgG on the interleukin-6 cascade in astrocytes via activation of the JAK\/STAT3 signaling pathway","volume":"258","author":"Du","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.msard.2025.106351_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107827","article-title":"Affinity-matured `aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders","volume":"162","author":"Duan","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.msard.2025.106351_bib0022","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fimmu.2018.01169","article-title":"Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and neuromyelitis optica from preclinical to","volume":"9","author":"Fl\u00f3rez-Grau","year":"2018","journal-title":"Clin. Trials. Front Immunol."},{"key":"10.1016\/j.msard.2025.106351_bib0023","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","article-title":"Eculizumab: a review in neuromyelitis optica spectrum disorder","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2025.106351_bib0024","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/cns.12559","article-title":"Impact of autologous mesenchymal stem cell infusion on neuromyelitis optica spectrum disorder: a pilot, 2-year observational study","volume":"22","author":"Fu","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.msard.2025.106351_bib0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40263-023-00995-9","article-title":"Satralizumab: a review in neuromyelitis optica spectrum disorder","volume":"37","author":"Fung","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2025.106351_bib0026","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica","volume":"8","author":"Giovannelli","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0027","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106351_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: a systematic review","volume":"9","author":"Holzer","year":"2023","journal-title":"RMD Open."},{"key":"10.1016\/j.msard.2025.106351_bib0029","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2011.04.008","article-title":"Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice","volume":"306","author":"Kim","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106351_bib0031","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/1744666X.2023.2151441","article-title":"An update on biologic treatments for neuromyelitis optica spectrum disorder","volume":"19","author":"Kim","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106351_bib0032","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200071","article-title":"Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar","volume":"10","author":"Kleiter","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106351_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032336","article-title":"Dual role of B cells in multiple sclerosis","volume":"24","author":"Kumar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106351_bib0034","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000973","article-title":"CNS autoimmune responses in BCMA-deficient mice provide insight for the failure of atacicept in MS","volume":"8","author":"Kumar","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106351_bib0035","article-title":"Role of toll-like receptors in neuroimmune diseases: therapeutic targets and problems","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106351_bib0036","article-title":"ACT001 relieves NMOSD symptoms by reducing astrocyte damage with an autoimmune antibody","volume":"28","author":"Li","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.msard.2025.106351_bib0037","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/glia.23512","article-title":"Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica","volume":"66","author":"Liu","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.msard.2025.106351_bib0038","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4049\/jimmunol.1301513","article-title":"Therapeutic efficacy of suppressing the Jak\/STAT pathway in multiple models of experimental autoimmune encephalomyelitis","volume":"192","author":"Liu","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2025.106351_bib0039","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12974-023-02997-2","article-title":"Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder","volume":"20","author":"Liu","year":"2023","journal-title":"J. Neuroinflamm"},{"key":"10.1016\/j.msard.2025.106351_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.783304","article-title":"Can immune tolerance Be re-established in neuromyelitis optica?","volume":"12","author":"Loda","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0041","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/156720212803530708","article-title":"Human umbilical cord mesenchymal stem cell therapy on neuromyelitis optica","volume":"9","author":"Lu","year":"2012","journal-title":"Curr. Neurovasc. Res."},{"key":"10.1016\/j.msard.2025.106351_bib0042","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3389\/fneur.2020.00967","article-title":"IV\/IT hUC-MSCs infusion in RRMS and NMO: a 10-year follow-up study","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109004","article-title":"Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: a modeling analysis of literature aggregate data","volume":"110","author":"Luo","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2025.106351_bib0044","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/glia.24271","article-title":"Remyelination in neuromyelitis optica spectrum disorder is promoted by edaravone through mTORC1 signaling activation","volume":"71","author":"Luo","year":"2023","journal-title":"Glia"},{"key":"10.1016\/j.msard.2025.106351_bib0045","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/imm.13416","article-title":"The role of Bruton's tyrosine kinase in the immune system and disease","volume":"164","author":"McDonald","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.msard.2025.106351_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102736","article-title":"B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE)","volume":"20","author":"M\u00f6ckel","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2025.106351_bib0047","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1007\/s00415-023-11710-5","article-title":"High-efficacy therapies reduce clinical and radiological events more effectively than traditional treatments in neuromyelitis optica spectrum disorder","volume":"270","author":"Moog","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105502","article-title":"Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: results from a Japanese claims database","volume":"84","author":"Nakashima","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106351_bib0049","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231181177","article-title":"Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan","volume":"16","author":"Nakashima","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106351_bib0050","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40263-022-00949-7","article-title":"Inebilizumab: a review in neuromyelitis optica spectrum disorder","volume":"36","author":"Nie","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2025.106351_bib0051","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0052","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jnnp-2022-330714","article-title":"Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum","volume":"94","author":"Park","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106351_bib0053","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0054","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106351_bib0055","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders\u2014from mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0056","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.msard.2025.106351_bib0057","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/13524585211047223","article-title":"Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u2a7e4\u2009years in the N-MOmentum trial","volume":"28","author":"Rensel","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106351_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton's tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106351_bib0059","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fimmu.2019.00095","article-title":"Toll-like receptor signaling drives btk-mediated autoimmune disease","volume":"10","author":"Rip","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106351_bib0060","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28052400","article-title":"Bruton's tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials","volume":"28","author":"Rozkiewicz","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.msard.2025.106351_bib0061","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106351_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105452","article-title":"Predictors of azathioprine and mycophenolate mofetil response in patients with neuromyelitis optica spectrum disorder: a cohort study","volume":"83","author":"San Martin","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106351_bib0063","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/cns.13836","article-title":"Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): novel insights into therapeutic possibilities in NMOSD","volume":"28","author":"Shi","year":"2022","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.msard.2025.106351_bib0064","first-page":"165","article-title":"Disruption of the blood-brain barrier in inflammatory neurological diseases","volume":"65","author":"Shimizu","year":"2013","journal-title":"Brain Nerve"},{"key":"10.1016\/j.msard.2025.106351_bib0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103730","article-title":"Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): b cell monitoring-based administration","volume":"60","author":"Tahara","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106351_bib0067","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0068","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14728222.2020.1732927","article-title":"Emerging therapeutic targets for neuromyelitis optica spectrum disorder","volume":"24","author":"Tradtrantip","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.msard.2025.106351_bib0069","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0070","doi-asserted-by":"crossref","first-page":"e14158","DOI":"10.1111\/ijcp.14158","article-title":"The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: a real-world study from Turkey","volume":"75","author":"Uzunk\u00f6pr\u00fc","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.msard.2025.106351_bib0071","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10875-012-9709-9","article-title":"Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse","volume":"32","author":"Wang","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106351_bib0072","doi-asserted-by":"crossref","first-page":"e00648","DOI":"10.1002\/brb3.648","article-title":"Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission","volume":"7","author":"Wang","year":"2017","journal-title":"Brain Behav."},{"key":"10.1016\/j.msard.2025.106351_bib0073","article-title":"Targeting chemoattractant chemokine (C\u2013C motif) ligand 2 derived from astrocytes is a promising therapeutic approach in the treatment of neuromyelitis optica spectrum disorders","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106351_bib0074","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0075","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0076","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40120-021-00295-8","article-title":"Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder","volume":"11","author":"Wingerchuk","year":"2022","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106351_bib0077","article-title":"Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: a survival meta-analysis of randomized controlled trials","volume":"2","author":"Xu","year":"2022","journal-title":"Adv. Ophthalmol. Pract. Res."},{"key":"10.1016\/j.msard.2025.106351_bib0078","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106351_bib0079","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12974-018-1162-0","article-title":"Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder","volume":"15","author":"Yamashita","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106351_bib0080","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00415-022-11364-9","article-title":"A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder","volume":"270","author":"Yang","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0081","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40478-016-0309-4","article-title":"Clobetasol promotes remyelination in a mouse model of neuromyelitis optica","volume":"4","author":"Yao","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.msard.2025.106351_bib0082","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.860083","article-title":"Human umbilical cord mesenchymal stem cells to treat neuromyelitis optica spectrum disorder (hUC-MSC-NMOSD): a study protocol for a prospective, multicenter, randomized, placebo-controlled clinical trial","volume":"13","author":"Yao","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0083","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/ana.26623","article-title":"Aquaporin-4 antibody dynamics and relapse risk in seropositive neuromyelitis Optica spectrum disorder treated with immunosuppressants","volume":"93","author":"Yin","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0084","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1007\/s00415-023-11641-1","article-title":"Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis","volume":"270","author":"Yin","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0085","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11910-023-01287-x","article-title":"A clinical approach to existing and emerging therapeutics in Neuromyelitis Optica spectrum disorder","volume":"23","author":"Yong","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2025.106351_bib0086","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106351_bib0087","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","article-title":"Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica","volume":"123","author":"Zhang","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2025.106351_bib0088","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500094X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500094X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T15:42:39Z","timestamp":1746546159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500094X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":88,"alternative-id":["S221103482500094X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106351","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in maintenance therapies for neuromyelitis optica spectrum disorders: A new era of targeted drugs","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106351"}}